UC-MSC and Secretome
Biologic
UC-MSC and Secretome is one of 26 biologic programs targeting Sepsis. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Micardis
Boehringer IngelheimPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Levaquin
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UC-MSC and Secretome. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- PPT. Prodia Stem Cell Indonesia